Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555997 · ClinicalTrials.gov registry record · Phase 2
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 7
- Study locations
NCT00555997 is a Phase 2 study of Major Depressive Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 120 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00555997, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD). Outpatients suffering from MDD will be treated with either ziprasidone or placebo for 12 weeks. Hypothesis: There will be a statistically significant difference in the magnitude of response, as measured by a decrease in baseline 17-item Hamilton Depression Rating Scale (HAM-D-17) scores, between the two treatment groups; the reduction in HAM-D-17 scores will be greater in the ziprasidone monotherapy group than in the placebo group.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziprasidone
Study Locations (7)
Connecticut
- University of Connecticut Health Center - Farmington
- Comprehensive Psychiatric Care - Norwich
Massachusetts
- Massachusetts General Hosptial - Boston
- Cambridge Health Alliance - Cambridge
California
- Cedars-Sinai Medical Center - Los Angeles
Illinois
- Psychiatric Medicine Associates, L.L.C. - Chicago
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555997
The ClinicalTrials.gov registry entry for NCT00555997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00555997 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT00555997 about?
NCT00555997 is a clinical study titled "A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder". This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD). Outpatients suffering from MDD will be treated with either ziprasidone or placebo for 12 weeks. Hypothesis: There will be a statistically significant di...
What is the current status of trial NCT00555997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-03. Estimated completion is 2010-06.
What conditions does trial NCT00555997 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00555997?
The interventions under investigation include: Placebo (DRUG), Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00555997?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00555997 being conducted?
This trial has 7 study locations across California, Connecticut, Illinois, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.